share_log

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K:重大事件
美股SEC公告 ·  09/09 09:05

Moomoo AI 已提取核心訊息

On September 3, 2024, Allarity Therapeutics, Inc. held its Annual Meeting where several key decisions were made by the stockholders. The stockholders approved an amendment to the Allarity Therapeutics Inc. 2021 Equity Incentive Plan, increasing the number of shares authorized for grant from 2,168,330 to 10,594,876. Additionally, two amendments to the company's Certificate of Incorporation were approved and subsequently filed with the Secretary of State of Delaware on September 9, 2024. The first amendment reduced the number of authorized shares from 750,500,000 to 250,500,000 and the second effected a 1-for-30 reverse stock split of the common stock, which began trading on a split-adjusted basis on the Nasdaq Capital Market on September 11, 2024. The reverse stock split resulted in every 30 shares of issued and outstanding common stock being combined...Show More
On September 3, 2024, Allarity Therapeutics, Inc. held its Annual Meeting where several key decisions were made by the stockholders. The stockholders approved an amendment to the Allarity Therapeutics Inc. 2021 Equity Incentive Plan, increasing the number of shares authorized for grant from 2,168,330 to 10,594,876. Additionally, two amendments to the company's Certificate of Incorporation were approved and subsequently filed with the Secretary of State of Delaware on September 9, 2024. The first amendment reduced the number of authorized shares from 750,500,000 to 250,500,000 and the second effected a 1-for-30 reverse stock split of the common stock, which began trading on a split-adjusted basis on the Nasdaq Capital Market on September 11, 2024. The reverse stock split resulted in every 30 shares of issued and outstanding common stock being combined into one share, with fractional shares rounded up to the next whole number. Adjustments were made to the per share exercise price and the number of shares purchasable upon exercise of outstanding stock options, as well as the number of shares reserved for future issuance under the Plan. The company's trading symbol remained 'ALLR' with a new CUSIP number post-split. During the Annual Meeting, stockholders also voted on the election of directors, the appointment of an independent auditor, and other proposals detailed in the Proxy Statement filed on August 20, 2024.
2024年9月3日,Allarity Therapeutics, Inc.召開了年度股東大會,在會議上做出了一些重要決定。股東們批准了對Allarity Therapeutics Inc. 2021股權激勵計劃的修正案,將授權股票發放數量從2,168,330股增加到10,594,876股。此外,公司的公司章程經過了兩個修正案的批准,並於2024年9月9日提交給了特拉華州的州務卿。第一個修正案將授權股票數量從7,505,000,000股減少到2,505,000,000股;第二個修正案對普通股進行了1比30的逆向股票拆分,從2024年9月11日開始在納斯達克資本市場以拆分調整後的價格進行交易。逆向...展開全部
2024年9月3日,Allarity Therapeutics, Inc.召開了年度股東大會,在會議上做出了一些重要決定。股東們批准了對Allarity Therapeutics Inc. 2021股權激勵計劃的修正案,將授權股票發放數量從2,168,330股增加到10,594,876股。此外,公司的公司章程經過了兩個修正案的批准,並於2024年9月9日提交給了特拉華州的州務卿。第一個修正案將授權股票數量從7,505,000,000股減少到2,505,000,000股;第二個修正案對普通股進行了1比30的逆向股票拆分,從2024年9月11日開始在納斯達克資本市場以拆分調整後的價格進行交易。逆向股票拆分導致每30股已發行和流通的普通股合併爲1股,碎股四捨五入至最接近的整數。對已發行的股票期權的行權價格和可行權的股票數量進行了相應調整,並對計劃下未來發行的股票數量進行了修改。公司的交易標的仍然是'ALLR',但拆分後有一個新的CUSIP編碼號。在年度股東大會上,股東還對董事選舉、獨立核數師任命和其他在2024年8月20日提交的委託聲明中詳細說明的提案進行了投票。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息